NewAmsterdam Pharma Company NV [NAMS] stock is trading at $21.84, up 8.33%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NAMS shares have gain 16.85% over the last week, with a monthly amount glided 18.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on June 10, 2025, when Stifel initiated its Buy rating and assigned the stock a price target of $44. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on June 04, 2025, and set its price target to $42. On December 30, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $48 on the stock. TD Cowen started tracking the stock assigning a Buy rating. Scotiabank initiated its recommendation with a Sector Outperform and recommended $35 as its price target on March 14, 2024. Guggenheim started tracking with a Buy rating for this stock on January 18, 2024, and assigned it a price target of $30. In a note dated January 16, 2024, Piper Sandler initiated an Overweight rating and provided a target price of $37 on this stock.
NewAmsterdam Pharma Company NV [NAMS] stock has fluctuated between $14.06 and $27.29 over the past year. Currently, Wall Street analysts expect the stock to reach $44.5 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $21.84 at the most recent close of the market. An investor can expect a potential return of 103.75% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
NewAmsterdam Pharma Company NV [NASDAQ:NAMS] reported sales of 47.14M for the trailing twelve months, which represents a growth of 112.56%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.02%, Pretax Profit Margin comes in at -3.97%, and Net Profit Margin reading is -3.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.33 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, NewAmsterdam Pharma Company NV’s Current Ratio is 19.98. Also, the Quick Ratio is 19.98, while the Cash Ratio stands at 18.29. Considering the valuation of this stock, the price to sales ratio is 52.02, the price to book ratio is 3.15.
Transactions by insiders
Recent insider trading involved Douglas F Kling, Affiliate, that happened on May 15 ’25 when 0.3 million shares were purchased. Affiliate, NAP PoolCo B.V. completed a deal on Apr 11 ’25 to buy 1.43 million shares. Meanwhile, Director Topper James N bought 1135.0 shares on Mar 26 ’25.
